Cargando…

Azithromycin and Tobramycin Therapy in Cystic Fibrosis Pulmonary Exacerbations: Less Is More?

Detalles Bibliográficos
Autores principales:	Thornton, Christina, Chin, Melanie, Somayaji, Ranjani
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Thoracic Society 2021
Materias:	Editorials
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7869784/ https://www.ncbi.nlm.nih.gov/pubmed/33522874 http://dx.doi.org/10.1513/AnnalsATS.202009-1227ED

Ejemplares similares

Azithromycin and the microbiota of cystic fibrosis sputum
por: Acosta, Nicole, et al.
Publicado: (2021)

Pulmonary Outcomes Associated with Long-Term Azithromycin Therapy in Cystic Fibrosis
por: Nichols, Dave P., et al.
Publicado: (2020)

Assessment of factors and interventions towards therapeutic adherence among persons with non-cystic fibrosis bronchiectasis
por: Thornton, Christina S., et al.
Publicado: (2022)

The pharmacokinetics and toxicity of morning vs. evening tobramycin dosing for pulmonary exacerbations of cystic fibrosis: A randomised comparison
por: Prayle, A.P., et al.
Publicado: (2016)

Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response
por: Lam, John C, et al.
Publicado: (2015)

Testing the effects of combining azithromycin with inhaled tobramycin for P. aeruginosa in cystic fibrosis: a randomised, controlled clinical trial
por: Nichols, David P, et al.
Publicado: (2022)

Platelets in Bronchiectasis: Player or Spectator?
por: Chin, Melanie, et al.
Publicado: (2021)

Evidence of Inhaled Tobramycin in Non-Cystic Fibrosis Bronchiectasis
por: Vendrell, Montserrat, et al.
Publicado: (2015)

Two Steps Forward: Improving the Management of Cystic Fibrosis Pulmonary Exacerbations
por: Waters, Valerie
Publicado: (2021)

Population Pharmacokinetics of Inhaled Tobramycin Powder in Cystic Fibrosis Patients
por: Ting, L, et al.
Publicado: (2014)

Long-term safety and efficacy of tobramycin in the management of cystic fibrosis
por: Vázquez-Espinosa, Emma, et al.
Publicado: (2015)

Clinical implications and characterization of Group A Streptoccoccus infections in adults with cystic fibrosis
por: Skolnik, Kate, et al.
Publicado: (2015)

Low Molecular Weight Chitosan-Coated PLGA Nanoparticles for Pulmonary Delivery of Tobramycin for Cystic Fibrosis
por: Al-Nemrawi, Nusaiba K., et al.
Publicado: (2018)

Tobramycin administered by the TOBI(®) Podhaler(®) for persons with cystic fibrosis: a review
por: VanDevanter, Donald R, et al.
Publicado: (2011)

Stenotrophomonas maltophilia natural history and evolution in the airways of adults with cystic fibrosis
por: Izydorczyk, Conrad, et al.
Publicado: (2023)

Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection
por: Greenwood, James, et al.
Publicado: (2017)

Can Identifying Pulmonary Exacerbation Phenotypes Guide New Treatment Approaches for Cystic Fibrosis?
por: Caverly, Lindsay J.
Publicado: (2022)

Effects of long-term tobramycin inhalation solution (TIS) once daily on exacerbation rate in patients with non-cystic fibrosis bronchiectasis
por: Terpstra, Lotte C., et al.
Publicado: (2022)

Is it Worth Adding Systemic Antibiotics to Inhalational Tobramycin Therapy to Treat Pseudomonas Infections in Cystic Fibrosis?
por: Karki, Kumar, et al.
Publicado: (2021)

Treatment satisfaction in cystic fibrosis: early patient experience with tobramycin inhalation powder
por: Greenberg, Jonathan, et al.
Publicado: (2016)

Eradication of Pseudomonas aeruginosa in cystic fibrosis patients with inhalation of dry powder tobramycin
por: Akkerman-Nijland, Anne M., et al.
Publicado: (2020)

Implementation of Model-Based Dose Adjustment of Tobramycin in Adult Patients with Cystic Fibrosis
por: Reverchon, Jérémy, et al.
Publicado: (2022)

Systematic review of the dry powder inhalers colistimethate sodium and tobramycin in cystic fibrosis
por: Uttley, Lesley, et al.
Publicado: (2013)

Economic Evaluation of Tobramycin Inhalation Powder for the Treatment of Chronic Pulmonary Pseudomonas aeruginosa Infection in Patients with Cystic Fibrosis
por: Panguluri, Srilekha, et al.
Publicado: (2017)

Acute hyperglycaemia in cystic fibrosis pulmonary exacerbations
por: Merjaneh, Lina, et al.
Publicado: (2020)

Tobramycin and Amikacin Delay Adhesion and Microcolony Formation in Pseudomonas aeruginosa Cystic Fibrosis Isolates
por: Olivares, Elodie, et al.
Publicado: (2017)

Cytomegalovirus-associated pulmonary exacerbation in patients with cystic fibrosis
por: Sawant, Akhil, et al.
Publicado: (2018)

Evaluation of Copeptin during Pulmonary Exacerbation in Cystic Fibrosis
por: Wojsyk-Banaszak, I., et al.
Publicado: (2019)

Lung ultrasound for the diagnosis of cystic fibrosis pulmonary exacerbation
por: Hassanzad, Maryam, et al.
Publicado: (2021)

The efficacy of azithromycin to prevent exacerbation of non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled studies
por: Li, Kui, et al.
Publicado: (2022)

Tobramycin inhalation powder for the treatment of pulmonary Pseudomonas aeruginosa infection in patients with cystic fibrosis: a review based on clinical evidence
por: Hamed, Kamal, et al.
Publicado: (2017)

Safety of intravenous tobramycin in combination with a variety of anti-pseudomonal antibiotics in children with cystic fibrosis
por: Deschamp, Ashley R, et al.
Publicado: (2017)

Home videos of cystic fibrosis patients using tobramycin inhalation powder: Relation of flow and cough
por: Meerburg, Jennifer J., et al.
Publicado: (2019)

Azithromycin: The Holy Grail to Prevent Exacerbations in Chronic Respiratory Disease?
por: Welte, Tobias
Publicado: (2019)

Azithromycin for idiopathic acute exacerbation of idiopathic pulmonary fibrosis: a retrospective single-center study
por: Kawamura, Kodai, et al.
Publicado: (2017)

1481. Clinical Outcomes of Escherichia coli Infections in Cystic Fibrosis (CF) Patients
por: Edwards, Brett, et al.
Publicado: (2018)

Glucose Tolerance during Pulmonary Exacerbations in Children with Cystic Fibrosis
por: Widger, John, et al.
Publicado: (2012)

Effect of esomeprazole versus placebo on pulmonary exacerbations in cystic fibrosis
por: DiMango, Emily, et al.
Publicado: (2014)

Inflammation and Airway Microbiota during Cystic Fibrosis Pulmonary Exacerbations
por: Zemanick, Edith T., et al.
Publicado: (2013)

Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations
por: Skolnik, Kate, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_npulj0jlpiqmi7cfgobbkgqek6